Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Neurocomputational Training to Improve Reward Responsiveness in Veterans With Anhedonia

4. november 2026 opdateret af: VA Office of Research and Development

Anhedonia, a reduction in motivation and in the ability to feel positive emotions, is widespread among Veterans across a range of psychiatric disorders. This impairment is associated with poorer psychosocial functioning and is resistant to first-line medication and psychotherapy treatments. However, interventions to improve anhedonia are sorely lacking. Reward learning supports motivation to seek rewards, and this mechanism can be enhanced by engaging in reward exploration. Our preliminary findings suggest that this approach can help improve reward responsiveness and positive mood among depressed and anxious individuals. Thus, the proposed research will test the preliminary efficacy of a computerized reward learning training in improving reward sensitivity and reducing anhedonia in Veterans. This new intervention could offer a novel remotely accessible treatment and help enhance the efficacy of existing evidence-based treatments for depression and other psychiatric conditions in Veterans.

Studieoversigt

Status

Status

Angiver den aktuelle rekrutteringsstatus eller den udvidede adgangsstatus.
Ikke rekrutterer endnu

Betingelser

Betingelser

Den sygdom, lidelse, syndrom, sygdom eller skade, der undersøges. På ClinicalTrials.gov kan tilstande også omfatte andre sundhedsrelaterede problemer, såsom levetid, livskvalitet og sundhedsrisici.

Intervention / Behandling

Intervention / Behandling

En proces eller handling, der er i fokus for en klinisk undersøgelse. Interventioner omfatter lægemidler, medicinsk udstyr, procedurer, vacciner og andre produkter, der enten er til undersøgelse eller allerede er tilgængelige. Interventioner kan også omfatte ikke-invasive tilgange, såsom uddannelse eller ændring af kost og motion.

Detaljeret beskrivelse

Anhedonia, which is characterized by reduced reward responsiveness and blunted positive affect, is widespread among Veterans across a range of psychiatric conditions, including depression and PTSD. Anhedonia manifests as reduced exploration of rewards in a range of domains, including social connectedness and workforce engagement, and is associated with poorer psychosocial functioning and reduced response to psychiatric treatment. Despite the prominence of anhedonia and these associated deficits, the treatment of impaired reward responsiveness and underlying mechanisms has received relatively little attention compared to punishment sensitivity and negative affect, particularly in Veteran populations. Moreover, pharmacological and behavioral treatments for depression have shown mixed results for anhedonia. Thus, there is a significant need for mechanistically informed interventions targeting anhedonia in Veterans.

Recent advances in computational psychiatry have shown that reward learning is a key top-down mechanism of reward exploration and foraging, which could be leveraged to develop cognitive training interventions for anhedonia. For instance, Bayesian reinforcement learning models have been particularly useful in disentangling various aspects of reward responsiveness, including reward prediction updating (learning) and reward maximization strategy. Within this framework, subjective anhedonia, has been robustly linked to lower learning-based reward maximization in the multi-arm bandit (MAB), a reward exploration task in which one must sample from various unknown options with the goal of maximizing rewards. Critically, a recent randomized clinical trial (RCT) from our group suggests that a MAB experimentally tuned to provide high variance of reward delivery can increase reward learning and associated reward maximization among clinically depressed and anxious individuals with anhedonia.

This proposal will capitalize on this approach to test the effectiveness of a novel neurocomputational cognitive training aimed at boosting reward sensitivity in Veterans with anhedonia. The specific aims are to : 1) examine the degree to which a reward learning training protocol (reward learning intensive training/ReLIT) changes the neurocomputations supporting reward sensitivity in Veterans with anhedonia (Aim 1); 2) test the effectiveness and optimal dosage of ReLIT in improving subjective markers of anhedonia, depression, and psychosocial functioning (Aim2), and 3) assess the degree to which the effects of ReLIT generalize to parallel measures of automatic affective processing (Aim 3).

In a 3-arm double-blind RCT, Veterans (N=120) with moderate to high anhedonia will be randomized to an 8-week protocol of: 1) sham training (non-active), 2) active ReLIT of moderate intensity, or 3) active ReLIT of high intensity. At baseline (pre-treatment), 8-weeks (post-treatment), and 16-weeks follow-up (8 weeks post-treatment), participants will complete an assessment MAB and 2 automatic affective processing tasks (while undergoing functional MRI for a subset of 75 participants). Bayesian computational modeling will be used to derive individual parameters of reward learning and reward maximization and to extract neural activity associated with dynamic updating of reward predictions. Clinical and affective measures will be collected at all 3 assessments and each treatment session.

This proposal aims to assess the preliminary efficacy of a novel intervention for improving healthy reward responsiveness and anhedonic pathology in Veterans, which is currently an underrepresented area of mental health treatment for Veterans. This mechanistically informed intervention could a) provide a scalable and cost-effective treatment for Veterans with anhedonia, relying on technology interface rather than clinician-guided administration, b) be used as an adjunctive training to boost the effectiveness of existing evidence-based treatments for Veterans, such as cognitive behavioral therapy.

Undersøgelsestype

Undersøgelsestype

Beskriver karakteren af ​​en klinisk undersøgelse. Undersøgelsestyper omfatter interventionelle undersøgelser (også kaldet kliniske forsøg), observationsundersøgelser (herunder patientregistre) og udvidet adgang.
Interventionel

Tilmelding (Anslået)

Tilmelding

Antallet af deltagere i en klinisk undersøgelse. Den "forventede" tilmelding er det mål for antallet af deltagere, som forskerne skal bruge til undersøgelsen.
120

Fase

Fase

Stadiet af et klinisk forsøg, der studerer et lægemiddel eller et biologisk produkt, baseret på definitioner udviklet af U.S. Food and Drug Administration (FDA). Fasen tager udgangspunkt i undersøgelsens formål, antallet af deltagere og andre karakteristika. Der er fem faser: Tidlig fase 1 (tidligere opført som fase 0), fase 1, fase 2, fase 3 og fase 4. Ikke relevant bruges til at beskrive forsøg uden FDA-definerede faser, herunder forsøg med enheder eller adfærdsmæssige indgreb.
  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiekontakt

Navn og kontaktoplysninger for den person, der kan besvare spørgsmål om tilmelding til en klinisk undersøgelse. Hvert sted, hvor undersøgelsen udføres, kan også have en specifik kontaktperson, som kan være bedre i stand til at besvare disse spørgsmål.

Studiesteder

  • Forenede Stater
    • California
      • San Diego, California, Forenede Stater, 92161-0002
        • VA San Diego Healthcare System, San Diego, CA
        • Ledende efterforsker:
          • Katia Harle, MD
        • Kontakt:

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Berettigelseskriterier

De nøglekrav, som personer, der ønsker at deltage i et klinisk studie, skal opfylde eller de egenskaber, de skal have. Kvalifikationskriterier består af både inklusionskriterier (som er nødvendige for at en person kan deltage i undersøgelsen) og eksklusionskriterier (som forhindrer en person i at deltage). Typer af berettigelseskriterier omfatter, om en undersøgelse accepterer raske frivillige, har alders- eller aldersgruppekrav eller er begrænset af køn.

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • being a Veteran
  • having at least moderate levels anhedonia (Snaith-Hamilton Pleasure Scale score>=20)
  • having sufficient vision and reading skills to complete the study protocol
  • being willing to attend treatment and assessment sessions

Exclusion Criteria:

  • lifetime history of psychotic or bipolar I disorder
  • neurological/neurodevelopmental disorders or sensory deficits that may impact cognitive function to preclude completion of study procedure (including past loss of consciousness > 24 hours)
  • taking certain psychotropic medications that may impact goal-directed task performance (e.g., benzodiazepines, sedative hypnotics); pre-existing stable doses (same regimen for at least 30 days) of psychotropic medications, such as selective serotonin reuptake inhibitors (SSRIs), will be allowed
  • recent (past 3 months) or current severe alcohol or substance use disorder necessitating prioritization of substance use treatment
  • recent (past month) or current risk of suicidal/homicidal behavior necessitating urgent higher level of care
  • undergoing concurrent neuromodulation or cognitive-behavioral psychotherapy targeting depression, anhedonia, and/or PTSD

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm

Deltagergruppe / Arm

En gruppe eller undergruppe af deltagere i et klinisk forsøg, der modtager en specifik intervention/behandling eller ingen intervention i henhold til forsøgets protokol.
Intervention / Behandling

Intervention / Behandling

En proces eller handling, der er i fokus for en klinisk undersøgelse. Interventioner omfatter lægemidler, medicinsk udstyr, procedurer, vacciner og andre produkter, der enten er til undersøgelse eller allerede er tilgængelige. Interventioner kan også omfatte ikke-invasive tilgange, såsom uddannelse eller ændring af kost og motion.
Eksperimentel: ReLIT - Moderate Intensity

This arm provides a moderate dose of the experimental treatment, i.e., ReLIT (Reward Learning Intensive Training).
Adfærdsmæssigt: ReLIT (Reward Learning Intensive Training)

This arm provides an active reward learning training.
Eksperimentel: ReLIT - High Intensity

This arm provides a high dose of the experimental treatment, i.e., ReLIT (Reward Learning Intensive Training).
Adfærdsmæssigt: ReLIT (Reward Learning Intensive Training)

This arm provides an active reward learning training.
Sham-komparator: ST (Sham Training)

This arm provides a non-training protocol matched for time and reward environment.
Adfærdsmæssigt: ST (Sham Training)

This arm provides an inactive reward learning training.

Hvad måler undersøgelsen?

Primære resultatmål

Primære resultatmål

I et klinisk studies protokol er det planlagte resultatmål, der er det vigtigste for at evaluere effekten af ​​en intervention/behandling. De fleste kliniske undersøgelser har ét primært resultatmål, men nogle har mere end ét.
Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Snaith-Hamilton Pleasure Scale (SHAPS)
Tidsramme: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Measure of anhedonia. Score range from 14 to 56, with higher scores indicating greater anhedonia severity.
Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Reward Maximization
Tidsramme: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Computational parameter derived from participants' choices in a reinforcement learning task, capturing the degree to which individuals select the options they predict to be most rewarding.
Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Neural Activation to Reward Prediction Errors (RPEs)
Tidsramme: Baseline, Post-Treatment (8 weeks)

Average BOLD (Blood-Oxygenation-Level Dependent) % signal change (i.e., activation) associated with individuals' model-based RPE (difference between expected probability of reward and actual outcome received) during reinforcement learning.
Baseline, Post-Treatment (8 weeks)

Sekundære resultatmål

Sekundære resultatmål

I en klinisk undersøgelses protokol er et planlagt resultatmål, der ikke er lige så vigtigt som det primære resultatmål for at evaluere effekten af ​​en intervention, men som stadig er af interesse. De fleste kliniske undersøgelser har mere end ét sekundært resultatmål.
Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
World Health Organization Quality of Life Scale (WHOQOL-BREF)
Tidsramme: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Measures quality of life and life satisfaction. Includes 4 domain subscales: physical health (range 7-35), psychological health (range 6-30), social relationships (range 3-15), and environment (range 8-42). Higher scores indicate higher quality of life.
Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Patient Health Questionnaire-9 (PHQ-9)
Tidsramme: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Measures depression severity. Scores range from 0 to 27. Higher scores indicate greater depression severity.
Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Approach Bias
Tidsramme: Baseline, Post-Treatment (8 weeks)

This metric assesses the degree to which individuals display an implicit approach bias towards positive/rewarding cues in an approach-avoidance task. It is computed as the mean response time difference between approach-positive and avoid-positive choices.
Baseline, Post-Treatment (8 weeks)
Automatic Positive Affective Processing
Tidsramme: Baseline, Post-Treatment (8 weeks)

A measure of implicit bias towards positive relative to negative cues in an affective go/no-go task, as measured but the standardized rate of hits (accurate identification of positive cues) minus standardized rate of false alarms (inaccurate identification of negative cues as positive).
Baseline, Post-Treatment (8 weeks)
Neural Activation Associated with Implicit Processing of Positive Cues
Tidsramme: Baseline, Post-Treatment (8 weeks)

Average BOLD (Blood-Oxygenation-Level Dependent) % signal change (i.e., activation) associated with the contrast of positive-Go vs negative-Go trials in an affective go/no-go task.
Baseline, Post-Treatment (8 weeks)
Neural Activation Associated with Approach Bias
Tidsramme: Baseline, Post-Treatment (8 weeks)

Average BOLD (Blood-Oxygenation-Level Dependent) % signal change (i.e., activation) associated with the contrast of (positive-approach vs positive-avoid) minus (neutral-approach vs neutral-avoid) in an approach-avoidance task.
Baseline, Post-Treatment (8 weeks)

Andre resultatmål

Andre resultatmål

For kliniske forsøg en planlagt måling beskrevet i protokollen, der bruges til at bestemme effekten af ​​en intervention/behandling på deltagerne. Til observationsstudier, en måling eller observation, der bruges til at beskrive mønstre af sygdomme eller egenskaber eller sammenhænge med eksponeringer, risikofaktorer eller behandling. Typer af resultatmål omfatter primært resultatmål og sekundært resultatmål.
Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Inventory of Psychosocial Functioning (IPF)
Tidsramme: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

The scale measures the degree of impairment in ability to interact effectively with others, fulfill social roles (e.g., work), and meet personal and societal expectations. It is comprised of 7 subscales. Each item ranges from 0 to 6. Higher scores indicate greater degree of impairment in psychosocial functioning.
Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Mood and Anxiety Symptoms Questionnaire (MASQ-D30)
Tidsramme: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Measure of anhedonic depression, anxiety, and stress symptoms. The scale has three subscales (general distress, anhedonic depression, and anxious arousal) , with each score ranging from 10 to 50. Higher scores indicate greater severity of symptoms.
Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Reaction to Treatment Questionnaire
Tidsramme: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Measure of treatment satisfaction and credibility of treatment rationale. Total scores range from 3 to 27, with higher scores indicating greater satisfaction and credibility in the treatment.
Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Liebowitz Social Anxiety Scale (LSAS)
Tidsramme: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Assesses the impact of social anxiety on multiple aspects of life. Scores range from 0 to 144, with higher scores indicating greater social anxiety.
Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Positive and Negative Affect Schedule (PANAS)
Tidsramme: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Assess positive and negative mood using a 5-point frequency scale (1-5). Each subscale (positive or negative affect) range from 10 to 50.
Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Social Connectedness Scale - Revised (SCS-R)
Tidsramme: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Measures the degree to which individuals feel connected to others in their social environment. Scores range from 20 to 120, where higher scores indicate a stronger, healthier sense of social connectedness.
Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Foraging Task
Tidsramme: Baseline, Post-Treatment (8 weeks)

Measures performance and computational parameters associated with approach and avoidance biases in a dynamic foraging task.
Baseline, Post-Treatment (8 weeks)
Beck Anxiety Inventory (BAI)
Tidsramme: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

This scale measures anxiety severity. Scores range from 0 to 63, with higher scores indicating greater anxiety severity.
Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
PTSD Checklist-5 (PCL-5)
Tidsramme: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Measures post-traumatic stress disorder (PTSD) severity. Scores range from 0 to 80, with higher scores indicating greater PTSD severity.
Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Behavioral Activation for Depression Scale (BADS)
Tidsramme: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

This scale measures changes in activation and avoidance behaviors. Items are measured on a 7-point Likert scale (0-6). Scores range from 0 to 150, with higher scores indicating greater behavioral activation.
Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Quick Structured Clinical Interview for DSM-5 (QuickSCID-5)
Tidsramme: Baseline , Post-Treatment (8-weeks)

Measures psychological diagnoses, which will be used to assess primary diagnostic category (i.e., depressive vs traumatic stress/anxiety disorder).
Baseline , Post-Treatment (8-weeks)
Neural Activation to Anticipated Reward
Tidsramme: Baseline, Post-Treatment (8 weeks)

Average BOLD (Blood-Oxygenation-Level Dependent) % signal change (i.e., activation) associated with individuals' model-based reward prediction/anticipation for chosen options during reinforcement learning.
Baseline, Post-Treatment (8 weeks)
Learning Rate
Tidsramme: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Computational parameter derived from participants' choices in a reinforcement learning task, capturing the degree to which individuals are updating their dynamic reward predictions.
Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)
Specific Loss of Interest and Pleasure Scale (SLIPS)
Tidsramme: Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

This is a measure of social anhedonia, i.e., hypo-responsiveness to social rewards, such as positive human interactions. Scores range from 0 to 69. Higher scores indicate greater severity of social anhedonia.
Baseline, Post-Treatment (8 weeks), Follow-Up (16 weeks)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Sponsor

Den organisation eller person, der igangsætter undersøgelsen, og som har myndighed og kontrol over undersøgelsen.
VA Office of Research and Development

Efterforskere

Efterforskere

En forsker involveret i et klinisk studie. Beslægtede termer omfatter stedets principal investigator, site sub-investigator, studieformand, undersøgelsesleder og undersøgelseshovedinvestigator.
  • Ledende efterforsker: Katia Harle, MD, VA San Diego Healthcare System, San Diego, CA

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

Studiestart

Den faktiske dato, hvor den første deltager blev tilmeldt en klinisk undersøgelse. Den "forventede" undersøgelses startdato er den dato, som forskerne tror vil være undersøgelsens startdato.
1. juli 2027

Primær færdiggørelse (Anslået)

Primær færdiggørelse

Den dato, hvor den sidste deltager i et klinisk studie blev undersøgt eller modtog en intervention for at indsamle endelige data for det primære resultatmål. Hvorvidt det kliniske studie sluttede i henhold til protokollen eller blev afsluttet, påvirker ikke denne dato. For kliniske undersøgelser med mere end ét primært resultatmål med forskellige afslutningsdatoer refererer dette udtryk til den dato, hvor dataindsamlingen er afsluttet for alle de primære resultatmål. Den "forventede" primære afslutningsdato er den dato, som forskerne tror vil være den primære afslutningsdato for undersøgelsen.
31. december 2030

Studieafslutning (Anslået)

Studieafslutning

Den dato, hvor den sidste deltager i et klinisk studie blev undersøgt eller modtog en intervention/behandling for at indsamle endelige data for de primære resultatmål, sekundære udfaldsmål og uønskede hændelser (det vil sige den sidste deltagers sidste besøg). Den "forventede" undersøgelses afslutningsdato er den dato, som forskerne tror vil være undersøgelsens afslutningsdato.
31. marts 2031

Datoer for studieregistrering

Først indsendt

Først indsendt

Den dato, hvor undersøgelsens sponsor eller investigator første gang indsendte en undersøgelsespost til ClinicalTrials.gov. Der er typisk en forsinkelse på et par dage mellem den første indsendte dato og postens tilgængelighed på ClinicalTrials.gov (den første offentliggjorte dato).
4. november 2026

Først indsendt, der opfyldte QC-kriterier

Først indsendt, der opfyldte QC-kriterier

Den dato, hvor undersøgelsens sponsor eller investigator første gang indsender en undersøgelsespost, der er i overensstemmelse med National Library of Medicine (NLM) kvalitetskontrol (QC) gennemgangskriterier. Sponsoren eller investigatoren skal muligvis revidere og indsende en undersøgelsespost en eller flere gange, før NLM's kvalitetskontrolkriterier er opfyldt. Det er sponsorens eller investigatorens ansvar at sikre, at undersøgelsesposten er i overensstemmelse med NLM QC-gennemgangskriterierne.
4. november 2026

Først opslået (Faktiske)

Først opslået

Datoen, hvor undersøgelsesposten først var tilgængelig på ClinicalTrials.gov efter National Library of Medicine (NLM) kvalitetskontrol (QC) gennemgang er afsluttet. Der er typisk en forsinkelse på et par dage mellem den dato, hvor undersøgelsens sponsor eller investigator indsendte undersøgelsesposten, og den første offentliggjorte dato.
10. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

Sidste opdatering sendt

Den seneste dato, hvor ændringer i en undersøgelsespost blev gjort tilgængelig på ClinicalTrials.gov. Der kan være en forsinkelse mellem det tidspunkt, hvornår ændringerne blev indsendt til ClinicalTrials.gov af undersøgelsens sponsor eller investigator (datoen for sidste opdatering afsendt) og den sidste opdatering, der blev sendt.
10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

Den seneste dato, hvor undersøgelsens sponsor eller investigator indsendte ændringer til en undersøgelsespost, der er i overensstemmelse med National Library of Medicine (NLM) kvalitetskontrol (QC) gennemgangskriterier. Det er sponsorens eller investigatorens ansvar at sikre, at undersøgelsesposten er i overensstemmelse med NLM QC-gennemgangskriterierne.
4. november 2026

Sidst verificeret

Sidst verificeret

Den seneste dato, hvor undersøgelsens sponsor eller investigator bekræftede oplysningerne om en klinisk undersøgelse på ClinicalTrials.gov som nøjagtige og aktuelle. Hvis en undersøgelse med rekrutteringsstatus som rekruttering; rekrutterer endnu ikke; eller aktiv, ikke rekruttering er ikke blevet bekræftet inden for de seneste 2 år, er undersøgelsens rekrutteringsstatus vist som ukendt.
1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

Andre undersøgelses-id-numre

Andre identifikatorer eller ID-numre end NCT-nummeret, der er tildelt til en klinisk undersøgelse af undersøgelsens sponsor, finansieringsgivere eller andre. Disse numre kan omfatte unikke identifikatorer fra andre forsøgsregistre og National Institutes of Health-bevillingsnumre.
  • MHBC-006-26S

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

One or more data sets without personal identifiers will be generated during the data analysis phase of this study. The data sets will include all data underlying any publications generated by this study as well as statistical code, and therefore these will be sufficient to reproduce or verify any published findings.

Any HIPAA identifiers, or combinations of variables that could be used for re-identification, will be excluded, as will any proprietary information. The plan does not include any access to individually identifiable or proprietary data. Therefore, this plan will ensure the protection of personal privacy, the confidentiality of individually identifiable private information, and the security of proprietary data and information.

IPD-delingstidsramme

IPD and supporting information will become available upon completion of the study and publication of the the results.

IPD-delingsadgangskriterier

Final de-identified datasets in machine-readable format will be submitted to and accessed from PubMed Central (and similar sites); care will be taken to ensure that individuals cannot be re-identified using other publicly available information.

IPD-deling Understøttende informationstype

  • ANALYTIC_CODE

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Cookieindstillinger

Vi bruger cookies for at sikre, at vi giver dig den bedste oplevelse på vores hjemmeside. For flere detaljer skal du læse omhyggeligt vores Politik om beskyttelse af personlige oplysninger og cookies. ...>>>Du kan når som helst ændre dine præferencer eller trække dit samtykke tilbage ved at slette cookies fra din hjemmeside eller computer som beskrevet i politikken. Accepter det og vælg dine præferencer ved at markere de tilsvarende felter i afsnittet "Administrer indstillinger" nedenfor. Læs vores servicevilkår omhyggeligt, inden du fortsætter med at bruge nogen del af dette websted.
«Administrer indstillinger